NVP-AUY922 was evaluated in a phase I clinical trial concerning solid-organ malignancies (primarily breast, ovarian, and colon cancer), and a phase II clinical trial evaluation in NSCLC patients was also carried out by grouping to epidermal growth factor receptor (EGFR) mutations, KRAS proto-oncogene GTPase (KRAS) mutations, anaplastic lymphoma kinase (ALK) rearrangement, and wild-type NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.